What K Street is paying attention to this month politico.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from politico.com Daily Mail and Mail on Sunday newspapers.
Acg Advocacy: Newsguard Technologies
Alexander, Borovicka & O Shea Government Solutions (Fka Alexander & Borovicka Go: Volan Technology Inc.
Alpine Group Partners, LLC.: Enviva Holdings, Lp
Alpine Group Partners, LLC.: Takeda Pharmaceuticals America, Inc.
Alston & Bird LLP: USagainstalzheimers Action
Arent Fox LLP: Grand Street Settlement, Inc.
Bracewell LLP: Sustainable Opportunities Acquisition Corporation
Bramer Group, LLC: Ducommun Inc.
Capitol Counsel LLC: American Association Of Settlement Consultants
Capitol Counsel LLC: Rebuild Local News Coalition
Capitol Counsel LLC: United Spinal Association
Cavarocchi Ruscio Dennis Associates, L.L.C.: Cure Epilepsy
G2G Consulting: Lead Safe Cleveland Coalition
Grayrobinson Pa: City Of Apopka Fl
Hogan Lovells US LLP: Prodigy Education
AstraZeneca brings on a new outside firm politico.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from politico.com Daily Mail and Mail on Sunday newspapers.
POLITICO
Get the POLITICO Influence newsletter
Email
Sign Up
By signing up you agree to receive email newsletters or updates from POLITICO and you agree to our privacy policy and terms of service. You can unsubscribe at any time and you can contact us here. This sign-up form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Presented by Coalition for App Fairness
With Daniel Lippman and Zach Warmbrodt
VENUES STILL WAITING FOR CASH AFTER LOBBYING VICTORY: When the pandemic hit last year, concert and performing arts venues banded together to form the National Independent Venue Association, which spent months lobbying Congress to help them. They succeeded in December: Congress included a grant program for shuttered venues in the Covid relief.
Share:
EAGAN, Minn., Dec. 16, 2020 /PRNewswire/ In an effort to help assess the value of hemophilia A treatments relative to total health care costs and emergency department visits, Prime Therapeutics LLC (Prime) has finalized an arrangement with Takeda Pharmaceuticals America, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (NYSE:TAK) ( Takeda ) for the factor replacement product ADVATE
® [Antihemophilic Factor (Recombinant)], which is used in the treatment and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency).
Hemophilia treatment options have increased in recent years, including innovative therapies. However, these innovations come at a high price. Therefore, it is important to establish integrated medical and pharmacy benefit contracts between payers and product manufacturers on existing treatments. The arrangement between Prime and Takeda provides: